Think global-act local: Intravitreal drug delivery systems in chronic noninfectious uveitis

Ophthalmic Research

Volumn 49, Issue 2, 2013, Pages 59-65

  Hazirolan, Dicle ^a   Pleyer, Uwe ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Chronic noninfectious uveitis; Corticosteroids; Intravitreal drug delivery

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; INFLIXIMAB; METHOTREXATE; RANIBIZUMAB; RAPAMYCIN; TRIAMCINOLONE ACETONIDE; CORTICOSTEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN INHIBITOR;

BEHCET DISEASE; CATARACT; CATARACT EXTRACTION; CHRONIC NONINFECTIOUS UVEITIS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FLUORESCENCE ANGIOGRAPHY; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; LYMPHOMA; MACULAR THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; REVIEW; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; SUBRETINAL NEOVASCULARIZATION; SYMPATHETIC OPHTHALMIA; UVEITIS; VISION; VISUAL ACUITY; VITRITIS; VOGT KOYANAGI SYNDROME; INTRAVITREAL DRUG DELIVERY SYSTEM; INTRAVITREAL IMPLANT;

ANGIOGENESIS INHIBITORS; ANIMALS; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, POSTERIOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84873850802     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000345477     Document Type: Review

References (47)

1. Gregerson DS, Heuss ND, Lehmann U, McPherson SW: Evidence for extrathymic generation of regulatory T cells specific for a retinal antigen. Ophthalmic Res 2008; 40: 154-159
2. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE: Randomized comparison of systemic antiinflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The Multicenter Uveitis Steroid Treatment trial. Ophthalmology 2011; 118: 1916-1926
3. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW: Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; 117: 567-575
4. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL: Treatment of posterior uveitis with a fluocinolone acetonide implant: Three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201
5. Razeghinejad MR, Katz LJ: Steroid-induced iatrogenic glaucoma. Ophthalmic Res 2012; 47: 66-80
6. Menezo V, Lau C, Comer M, Lightman S: Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol 2005; 33: 16-21
7. Sallam A, Taylor SRJ, Lightman S: Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol 2011; 22: 517-522
8. Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A: Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: A comparative study. Ophthalmic Res 2009; 42: 81-86
9. Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T: Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Exp Ophthalmol 2009; 37: 389-396
10. Sallam A, Taylor SR, Habot-Wilner Z, Elgohary M, Do HH, McCluskey P, Lightman S: Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol 2012; 90:e323-e325
11. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I: Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther 2007; 23: 395-401
12. Chan WM, Lim E, Liu DT, Law RW, Lam DS: Intravitreal triamcinolone acetonide for choroidal granuloma in sarcoidosis. Am J Ophthalmol 2005; 139: 1116-1118
13. Moreker MR, Lodhi SA, Pathengay A: Role of intravitreal triamcinolone as an adjuvant in the management of Vogt-Koyanagi-Harada disease. Indian J Ophthalmol 2007; 55: 479-80
14. Ozdemir H, Karacorlu M, Karacorlu S: Intravitreal triamcinolone acetonide in sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol 2005; 243: 734-736
15. Jonas JB: Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res 2006; 38: 218-245
16. Rush R, Sheth S: Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration. Indian J Ophthalmol 2012; 60: 141-143
17. Vertes D, Snyers B, De Potter P: Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: A warning for the widespread use of intravitreous corticosteroids. Int Ophthalmol 2010; 30: 595-597
18. Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA,Wilensky JT: Treating chronic noninfectious posterior segment uveitis: The impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006;(suppl):1-16
19. Arndt C, Meunier I, Rebollo O, Martinenq C, Hamel C, Hattenbach LO: Electrophysiological retinal pigment epithelium changes observed with indocyanine green, trypan blue and triamcinolone. Ophthalmic Res 2010; 44: 17-23
20. Morse LS, Ashton P, Levy B, Mann ES, Eliott D: Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3- year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580-1586
21. Jain N, Stinnett SS, Jaffe GJ: Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion thirty-six-month results. Ophthalmology 2012; 119: 132-137
22. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group: Dexamethasone posteriorsegment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-1054, 1054.e1-e2
23. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM, Ozurdex HURON Study Group: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
24. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL: Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009; 116: 797-801
25. Bae JH, Lee SC: Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina 2012; 32: 1395-402
26. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F, Famous Study Group: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117: 1393-1399.e3
27. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon Y- H, Jacques M- L, Jiao J, Li X- Y, Whitcup SM: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146, e1133
28. Boyer DS, Faber DJ, Gupta SK, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM, the Ozurdex Champlain Study Group: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923
29. Pleyer U, Klamann M, Winterhalter S, Thurau S: Ozurdex: A new therapeutic option in uveitis - clinical outcome from two German uveitis centers. Abstract ARVO Annual Meeting, Fort Lauderdale, May 2012
30. Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Kopp I, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T: Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142: 176-193
31. Wickremasinghe SS, Ojaimi E, Lim L, Stawell R, McKelvie P, Zamir E: Intravitreal methotrexate as adjunctive, palliative therapy in intraocular T-cell lymphoma. Ocul Immunol Inflamm 2010; 18: 184-186
32. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H: Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006; 142: 883-885
33. Palakurthi NK, Correa ZM, Augsburger JJ, Banerjee RK:Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: A pilot study. J Ocul Pharmacol Th 2011; 27: 151-156
34. Patel RD, Momi RS, Hariprasad SM: Review of ranibizumab trials for neovascular agerelated macular degeneration. Semin Ophthalmol 2011; 26: 372-379
35. El- Mollayess GM, Noureddine BN, Bashshur ZF: Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 2011; 26: 69-76
36. Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L, Roca JA, Quiroz- Mercado H, Ruiz-Moreno JM, Serrano MA: Intravitreal bevacizumab for inflammatory choroidal neovascularization: Results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 2011; 31: 353-363
37. Julián K, Terrada C, Fardeau C, Cassoux N, Français C, LeHoang P, Bodaghi B: Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol 2011; 89: 179-184
38. Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N: Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 2011; 31: 871-879
39. Acharya NR, Hong KC, Lee SM: Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148: 303-309
40. Lasave AF, Zeballos DG, El- Haig WM, Díaz-Llopis M, Salom D, Arevalo JF: Short-term results of a single intravitreal bevacizumab (Avastin) injection versus a single intravitreal triamcinolone acetonide (Kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 2009; 17: 423-430
41. Hazirolan D, Stübiger N, Pleyer U: Light on the Horizon: biologicals in Behçet uveitis. Acta Ophthalmol 2012, E-pub ahead of print
42. Melo GB, Moraes Filho MN, Rodrigues EB, Regatieri CV, Dreyfuss JL, Penha FM, Pinheiro MM, Coimbra RC, Haapalainen EF, Farah ME: Toxicity and retinal penetration of infliximab in primates. Retina 2012; 32: 606-612
43. Farvardin M, Afarid M, Mehryar M, Hosseini H: Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30: 1530-1535
44. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N: Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30: 71-80
45. Shanmuganathan VA, Casely EM, Raj D, Powell RJ, Joseph A, Amoaku WM, Dua HS: The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005; 89: 666-669
46. Manzano RP, Peyman GA, Khan P, Kivilcim M, Chevez-Barrios P, Takahashi W: Testing intravitreal toxicity of rapamycin in rabbit eyes. Arq Bras Oftalmol 2009; 72: 18-22
47. Nguyen QD, Ibrahim M, Watters A: Primary endpoint results of the SAVE study - sirolimus as therapeutic approach to uveitis: A randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with noninfectious uveitis. Abstract ARVO Annual Meeting, Fort Lauderdale, May 2012